RDY vs. SMMT: A Head-to-Head Stock Comparison
Updated onHere’s a clear look at RDY and SMMT, comparing key factors like historical performance, profitability, financial strength, growth, dividend, and valuation.
Company Profile
RDY trades as an American Depositary Receipt (ADR), offering U.S. investors a convenient way to access its foreign-listed shares. In contrast, SMMT is a standard domestic listing.
| Symbol | RDY | SMMT |
|---|---|---|
| Company Name | Dr. Reddy's Laboratories Limited | Summit Therapeutics Inc. |
| Country | India | United States |
| GICS Sector | Health Care | Health Care |
| GICS Industry | Pharmaceuticals | Biotechnology |
| Market Capitalization | 12.00 billion USD | 18.43 billion USD |
| Exchange | NYSE | NasdaqGM |
| Listing Date | April 11, 2001 | March 5, 2015 |
| Security Type | ADR | Common Stock |
Historical Performance
This chart compares the performance of RDY and SMMT by tracking the growth of an initial $10,000 investment in each. Use the tabs to select the desired time period. Data is adjusted for dividends and splits.
Historical Performance at a Glance
| Symbol | RDY | SMMT |
|---|---|---|
| 5-Day Price Return | 1.37% | -4.63% |
| 13-Week Price Return | 1.54% | -3.26% |
| 26-Week Price Return | 5.49% | 12.14% |
| 52-Week Price Return | -9.00% | 87.21% |
| Month-to-Date Return | -0.31% | -5.93% |
| Year-to-Date Return | -8.92% | 39.00% |
| 10-Day Avg. Volume | 1.41M | 3.11M |
| 3-Month Avg. Volume | 1.67M | 4.24M |
| 3-Month Volatility | 19.75% | 97.40% |
| Beta | 0.68 | -1.20 |
Profitability
Return on Equity (TTM)
RDY
8.86%
Pharmaceuticals Industry
- Max
- 38.59%
- Q3
- 19.84%
- Median
- 11.90%
- Q1
- 5.63%
- Min
- -9.96%
RDY’s Return on Equity of 8.86% is on par with the norm for the Pharmaceuticals industry, indicating its profitability relative to shareholder equity is typical for the sector.
SMMT
-52.22%
Biotechnology Industry
- Max
- 77.14%
- Q3
- 10.76%
- Median
- -20.08%
- Q1
- -42.71%
- Min
- -119.20%
SMMT has a negative Return on Equity of -52.22%. This indicates the company is generating a loss for its shareholders, which can be a result of unprofitability or negative shareholder equity and is often a sign of financial distress.
Net Profit Margin (TTM)
RDY
16.95%
Pharmaceuticals Industry
- Max
- 34.51%
- Q3
- 17.73%
- Median
- 12.12%
- Q1
- 5.99%
- Min
- -7.73%
RDY’s Net Profit Margin of 16.95% is aligned with the median group of its peers in the Pharmaceuticals industry. This indicates its ability to convert revenue into profit is typical for the sector.
SMMT
-9,027.08%
Biotechnology Industry
- Max
- 59.44%
- Q3
- 16.21%
- Median
- -11.49%
- Q1
- -167.42%
- Min
- -409.07%
SMMT has a negative Net Profit Margin of -9,027.08%, indicating the company is operating at a net loss as its expenses exceeded its revenues.
Operating Profit Margin (TTM)
RDY
20.17%
Pharmaceuticals Industry
- Max
- 41.53%
- Q3
- 23.00%
- Median
- 16.24%
- Q1
- 9.24%
- Min
- -6.94%
RDY’s Operating Profit Margin of 20.17% is around the midpoint for the Pharmaceuticals industry, indicating that its efficiency in managing core business operations is typical for the sector.
SMMT
-8,108.33%
Biotechnology Industry
- Max
- 60.62%
- Q3
- 20.76%
- Median
- -12.41%
- Q1
- -181.14%
- Min
- -482.02%
SMMT has a negative Operating Profit Margin of -8,108.33%. This signifies the company is unprofitable at the operational level, as its core business expenses exceed its revenue.
Profitability at a Glance
| Symbol | RDY | SMMT |
|---|---|---|
| Return on Equity (TTM) | 8.86% | -52.22% |
| Return on Assets (TTM) | 5.93% | -41.67% |
| Net Profit Margin (TTM) | 16.95% | -9,027.08% |
| Operating Profit Margin (TTM) | 20.17% | -8,108.33% |
| Gross Profit Margin (TTM) | 68.36% | -- |
Financial Strength
Current Ratio (MRQ)
RDY
1.92
Pharmaceuticals Industry
- Max
- 4.49
- Q3
- 2.77
- Median
- 1.74
- Q1
- 1.26
- Min
- 0.11
RDY’s Current Ratio of 1.92 aligns with the median group of the Pharmaceuticals industry, indicating that its short-term liquidity is in line with its sector peers.
SMMT
5.13
Biotechnology Industry
- Max
- 19.31
- Q3
- 9.38
- Median
- 4.54
- Q1
- 2.45
- Min
- 0.76
SMMT’s Current Ratio of 5.13 aligns with the median group of the Biotechnology industry, indicating that its short-term liquidity is in line with its sector peers.
Debt-to-Equity Ratio (MRQ)
RDY
0.14
Pharmaceuticals Industry
- Max
- 2.44
- Q3
- 1.07
- Median
- 0.42
- Q1
- 0.11
- Min
- 0.00
RDY’s Debt-to-Equity Ratio of 0.14 is typical for the Pharmaceuticals industry, indicating its use of leverage is in line with the sector norm. This suggests a balanced approach to its capital structure.
SMMT
0.00
Biotechnology Industry
- Max
- 1.35
- Q3
- 0.64
- Median
- 0.09
- Q1
- 0.00
- Min
- 0.00
SMMT’s Debt-to-Equity Ratio of 0.00 is typical for the Biotechnology industry, indicating its use of leverage is in line with the sector norm. This suggests a balanced approach to its capital structure.
Interest Coverage Ratio (TTM)
RDY
13.50
Pharmaceuticals Industry
- Max
- 103.95
- Q3
- 44.18
- Median
- 9.83
- Q1
- 2.82
- Min
- -42.71
RDY’s Interest Coverage Ratio of 13.50 is positioned comfortably within the norm for the Pharmaceuticals industry, indicating a standard and healthy capacity to cover its interest payments.
SMMT
-121.35
Biotechnology Industry
- Max
- 72.37
- Q3
- 1.91
- Median
- -7.81
- Q1
- -63.90
- Min
- -153.80
SMMT has a negative Interest Coverage Ratio of -121.35. This indicates that its earnings were insufficient to cover even its operational costs, let alone its interest payments, signaling significant financial distress.
Financial Strength at a Glance
| Symbol | RDY | SMMT |
|---|---|---|
| Current Ratio (MRQ) | 1.92 | 5.13 |
| Quick Ratio (MRQ) | 1.37 | 4.94 |
| Debt-to-Equity Ratio (MRQ) | 0.14 | 0.00 |
| Interest Coverage Ratio (TTM) | 13.50 | -121.35 |
Growth
Revenue Growth
EPS Growth
Dividend
Dividend Yield (TTM)
RDY
0.64%
Pharmaceuticals Industry
- Max
- 6.98%
- Q3
- 3.32%
- Median
- 2.13%
- Q1
- 0.14%
- Min
- 0.00%
RDY’s Dividend Yield of 0.64% is consistent with its peers in the Pharmaceuticals industry, providing a dividend return that is standard for its sector.
SMMT
0.00%
Biotechnology Industry
- Max
- 0.00%
- Q3
- 0.00%
- Median
- 0.00%
- Q1
- 0.00%
- Min
- 0.00%
SMMT currently does not pay a dividend, resulting in a yield of 0%. This is a common strategy for growth-focused companies that prioritize reinvesting earnings, though it may be less typical in mature, income-oriented sectors.
Dividend Payout Ratio (TTM)
RDY
53.05%
Pharmaceuticals Industry
- Max
- 165.20%
- Q3
- 90.59%
- Median
- 49.13%
- Q1
- 28.91%
- Min
- 0.00%
RDY’s Dividend Payout Ratio of 53.05% is within the typical range for the Pharmaceuticals industry, suggesting a balanced approach between shareholder payouts and company reinvestment.
SMMT
0.00%
Biotechnology Industry
- Max
- 0.00%
- Q3
- 0.00%
- Median
- 0.00%
- Q1
- 0.00%
- Min
- 0.00%
SMMT has a Dividend Payout Ratio of 0%, indicating it does not currently pay a dividend. This is a common strategy for growth-oriented companies that reinvest all profits back into the business.
Dividend at a Glance
| Symbol | RDY | SMMT |
|---|---|---|
| Dividend Yield (TTM) | 0.64% | 0.00% |
| Dividend Payout Ratio (TTM) | 53.05% | 0.00% |
Valuation
Price-to-Earnings Ratio (TTM)
RDY
18.29
Pharmaceuticals Industry
- Max
- 42.51
- Q3
- 26.88
- Median
- 19.11
- Q1
- 15.12
- Min
- 0.00
RDY’s P/E Ratio of 18.29 is within the middle range for the Pharmaceuticals industry. This suggests its valuation is in line with the sector average, representing neither a significant premium nor a discount compared to its peers.
SMMT
--
Biotechnology Industry
- Max
- 60.14
- Q3
- 38.17
- Median
- 29.01
- Q1
- 15.12
- Min
- 0.00
P/E Ratio data for SMMT is currently unavailable.
Price-to-Sales Ratio (TTM)
RDY
3.10
Pharmaceuticals Industry
- Max
- 7.55
- Q3
- 4.54
- Median
- 2.11
- Q1
- 1.52
- Min
- 0.00
RDY’s P/S Ratio of 3.10 aligns with the market consensus for the Pharmaceuticals industry. This suggests its valuation, based on sales, is seen as standard and is on par with its competitors.
SMMT
19,902.10
Biotechnology Industry
- Max
- 76.98
- Q3
- 36.53
- Median
- 9.49
- Q1
- 4.49
- Min
- 0.00
With a P/S Ratio of 19,902.10, SMMT trades at a valuation that eclipses even the highest in the Biotechnology industry. This implies the market has priced in exceptionally optimistic scenarios for future revenue growth, posing considerable valuation risk.
Price-to-Book Ratio (MRQ)
RDY
2.84
Pharmaceuticals Industry
- Max
- 9.78
- Q3
- 4.96
- Median
- 2.23
- Q1
- 1.46
- Min
- 0.60
RDY’s P/B Ratio of 2.84 is within the conventional range for the Pharmaceuticals industry. This shows a balanced market view, where the stock’s price is neither at a significant premium nor a discount to the book value of its peers.
SMMT
60.92
Biotechnology Industry
- Max
- 20.53
- Q3
- 9.76
- Median
- 4.77
- Q1
- 2.49
- Min
- 0.59
At 60.92, SMMT’s P/B Ratio is at an extreme premium to the Biotechnology industry. This signifies that the market’s valuation is heavily reliant on future potential rather than its current net asset value, which can be a high-risk proposition.
Valuation at a Glance
| Symbol | RDY | SMMT |
|---|---|---|
| Price-to-Earnings Ratio (TTM) | 18.29 | -- |
| Price-to-Sales Ratio (TTM) | 3.10 | 19,902.10 |
| Price-to-Book Ratio (MRQ) | 2.84 | 60.92 |
| Price-to-Free Cash Flow Ratio (TTM) | 86.35 | -- |